PortalPublikationenProspective head-to-head comparison of C-choline-PET/MR and ...

Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer

Standard

Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. / Eiber, Matthias; Rauscher, Isabel; Souvatzoglou, Michael; Maurer, Tobias; Schwaiger, Markus; Holzapfel, Konstantin; Beer, Ambros J.

in: EUR J NUCL MED MOL I, Jahrgang 44, Nr. 13, 12.2017, S. 2179-2188.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Eiber, M, Rauscher, I, Souvatzoglou, M, Maurer, T, Schwaiger, M, Holzapfel, K & Beer, AJ 2017, 'Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer', EUR J NUCL MED MOL I, Jg. 44, Nr. 13, S. 2179-2188. https://doi.org/10.1007/s00259-017-3797-y

APA

Eiber, M., Rauscher, I., Souvatzoglou, M., Maurer, T., Schwaiger, M., Holzapfel, K., & Beer, A. J. (2017). Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. EUR J NUCL MED MOL I, 44(13), 2179-2188. https://doi.org/10.1007/s00259-017-3797-y

Vancouver

Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K et al. Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. EUR J NUCL MED MOL I. 2017 Dez;44(13):2179-2188. https://doi.org/10.1007/s00259-017-3797-y

Bibtex

@article{5cc6676075d44cad9bfd8c3d6156164e,
title = "Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer",
abstract = "PURPOSE: Whole-body integrated 11C-choline PET/MR might provide advantages compared to 11C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases.MATERIALS AND METHODS: Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR. Imaging datasets were read separately by two reader teams (team 1 and 2) assessing the presence of local recurrence, lymph node and bone metastases in predefined regions using a five-point scale. Detection rates were calculated. The diagnostic performance of PET/CT vs. PET/MR was compared using ROC analysis. Inter-observer and inter-modality variability, radiation exposure, and mean imaging time were evaluated. Clinical follow-up, imaging, and/or histopathology served as standard of reference (SOR).RESULTS: Seventy-five patients qualified for the final image analysis. A total of 188 regions were regarded as positive: local recurrence in 37 patients, 87 regions with lymph node metastases, and 64 regions with bone metastases. Mean detection rate between both readers teams for PET/MR was 84.7% compared to 77.3% for PET/CT (p > 0.05). Local recurrence was identified significantly more often in PET/MR compared to PET/CT by team 1. Lymph node and bone metastases were identified significantly more often in PET/CT compared to PET/MR by both teams. However, this difference was not present in the subgroup of patients with PSA values ≤2 ng/ml. Inter-modality and inter-observer agreement (K > 0.6) was moderate to substantial for nearly all categories. Mean reduction of radiation exposure for PET/MR compared to PET/CT was 79.7% (range, 72.6-86.2%). Mean imaging time for PET/CT was substantially lower (18.4 ± 0.7 min) compared to PET/MR (50.4 ± 7.9 min).CONCLUSIONS: 11C-choline PET/MR is a robust imaging modality for restaging biochemical recurrent PC and interpretations between different readers are consistent. It provides a higher diagnostic value for detecting local recurrence compared to PET/CT with the advantage of substantial dose reduction. Drawbacks of PET/MR are a substantially longer imaging time and a slight inferiority in detecting bone and lymph node metastases in patients with PSA values >2 ng/ml. Thus, we suggest the use of 11C-choline PET/MR especially for patients with low (≤2 ng/ml) PSA values, whereas PET/CT is preferable in the subgroup with higher PSA values.",
keywords = "Aged, Aged, 80 and over, Carbon Radioisotopes, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Prospective Studies, Prostatic Neoplasms, Recurrence, Whole Body Imaging, Clinical Trial, Comparative Study, Journal Article",
author = "Matthias Eiber and Isabel Rauscher and Michael Souvatzoglou and Tobias Maurer and Markus Schwaiger and Konstantin Holzapfel and Beer, {Ambros J}",
year = "2017",
month = dec,
doi = "10.1007/s00259-017-3797-y",
language = "English",
volume = "44",
pages = "2179--2188",
journal = "EUR J NUCL MED MOL I",
issn = "1619-7070",
publisher = "Springer",
number = "13",

}

RIS

TY - JOUR

T1 - Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer

AU - Eiber, Matthias

AU - Rauscher, Isabel

AU - Souvatzoglou, Michael

AU - Maurer, Tobias

AU - Schwaiger, Markus

AU - Holzapfel, Konstantin

AU - Beer, Ambros J

PY - 2017/12

Y1 - 2017/12

N2 - PURPOSE: Whole-body integrated 11C-choline PET/MR might provide advantages compared to 11C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases.MATERIALS AND METHODS: Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR. Imaging datasets were read separately by two reader teams (team 1 and 2) assessing the presence of local recurrence, lymph node and bone metastases in predefined regions using a five-point scale. Detection rates were calculated. The diagnostic performance of PET/CT vs. PET/MR was compared using ROC analysis. Inter-observer and inter-modality variability, radiation exposure, and mean imaging time were evaluated. Clinical follow-up, imaging, and/or histopathology served as standard of reference (SOR).RESULTS: Seventy-five patients qualified for the final image analysis. A total of 188 regions were regarded as positive: local recurrence in 37 patients, 87 regions with lymph node metastases, and 64 regions with bone metastases. Mean detection rate between both readers teams for PET/MR was 84.7% compared to 77.3% for PET/CT (p > 0.05). Local recurrence was identified significantly more often in PET/MR compared to PET/CT by team 1. Lymph node and bone metastases were identified significantly more often in PET/CT compared to PET/MR by both teams. However, this difference was not present in the subgroup of patients with PSA values ≤2 ng/ml. Inter-modality and inter-observer agreement (K > 0.6) was moderate to substantial for nearly all categories. Mean reduction of radiation exposure for PET/MR compared to PET/CT was 79.7% (range, 72.6-86.2%). Mean imaging time for PET/CT was substantially lower (18.4 ± 0.7 min) compared to PET/MR (50.4 ± 7.9 min).CONCLUSIONS: 11C-choline PET/MR is a robust imaging modality for restaging biochemical recurrent PC and interpretations between different readers are consistent. It provides a higher diagnostic value for detecting local recurrence compared to PET/CT with the advantage of substantial dose reduction. Drawbacks of PET/MR are a substantially longer imaging time and a slight inferiority in detecting bone and lymph node metastases in patients with PSA values >2 ng/ml. Thus, we suggest the use of 11C-choline PET/MR especially for patients with low (≤2 ng/ml) PSA values, whereas PET/CT is preferable in the subgroup with higher PSA values.

AB - PURPOSE: Whole-body integrated 11C-choline PET/MR might provide advantages compared to 11C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases.MATERIALS AND METHODS: Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR. Imaging datasets were read separately by two reader teams (team 1 and 2) assessing the presence of local recurrence, lymph node and bone metastases in predefined regions using a five-point scale. Detection rates were calculated. The diagnostic performance of PET/CT vs. PET/MR was compared using ROC analysis. Inter-observer and inter-modality variability, radiation exposure, and mean imaging time were evaluated. Clinical follow-up, imaging, and/or histopathology served as standard of reference (SOR).RESULTS: Seventy-five patients qualified for the final image analysis. A total of 188 regions were regarded as positive: local recurrence in 37 patients, 87 regions with lymph node metastases, and 64 regions with bone metastases. Mean detection rate between both readers teams for PET/MR was 84.7% compared to 77.3% for PET/CT (p > 0.05). Local recurrence was identified significantly more often in PET/MR compared to PET/CT by team 1. Lymph node and bone metastases were identified significantly more often in PET/CT compared to PET/MR by both teams. However, this difference was not present in the subgroup of patients with PSA values ≤2 ng/ml. Inter-modality and inter-observer agreement (K > 0.6) was moderate to substantial for nearly all categories. Mean reduction of radiation exposure for PET/MR compared to PET/CT was 79.7% (range, 72.6-86.2%). Mean imaging time for PET/CT was substantially lower (18.4 ± 0.7 min) compared to PET/MR (50.4 ± 7.9 min).CONCLUSIONS: 11C-choline PET/MR is a robust imaging modality for restaging biochemical recurrent PC and interpretations between different readers are consistent. It provides a higher diagnostic value for detecting local recurrence compared to PET/CT with the advantage of substantial dose reduction. Drawbacks of PET/MR are a substantially longer imaging time and a slight inferiority in detecting bone and lymph node metastases in patients with PSA values >2 ng/ml. Thus, we suggest the use of 11C-choline PET/MR especially for patients with low (≤2 ng/ml) PSA values, whereas PET/CT is preferable in the subgroup with higher PSA values.

KW - Aged

KW - Aged, 80 and over

KW - Carbon Radioisotopes

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Positron Emission Tomography Computed Tomography

KW - Prospective Studies

KW - Prostatic Neoplasms

KW - Recurrence

KW - Whole Body Imaging

KW - Clinical Trial

KW - Comparative Study

KW - Journal Article

U2 - 10.1007/s00259-017-3797-y

DO - 10.1007/s00259-017-3797-y

M3 - SCORING: Journal article

C2 - 28803358

VL - 44

SP - 2179

EP - 2188

JO - EUR J NUCL MED MOL I

JF - EUR J NUCL MED MOL I

SN - 1619-7070

IS - 13

ER -